Skip to Content
Postdoctoral Research Scholar
Address: 3-701D BSB
Phone: (319) 335-7819
Mentor: Hillel Haim, MD, PhD
PhD Institution: Monash University, Melbourne, Australia
My research focuses on understanding how envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) evolve during the course of infection and their complex interplay with the host antibody response.
Gray LR, Turville SG, Hitchen TL, Cheng WJ, Ellett AM, Salimi H, Roche MJ, Wesselingh SL, Gorry PR, Churchill MJ. HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles. PLoS One, 2014 28;9(2).
Salimi H, Roche M, Webb N, Gray LR, Chikere K, Sterjovski J, Ellett A, Wesselingh SL, Ramsland PA, Lee B, Churchill MJ, Gorry PR (2013). Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. J Leukoc Biol, 2013, 93(1): 113-26.
Roche M*, Salimi H*, Duncan R, Wilkinson B, Chikere K, Moore M, Webb N, Zappi H, Sterjovski J, Flynn JK, Ellett A, Gray LR, Lee B, Jubb B, Westby M, Ramsland PA, Lewin SR, Payne R, Churchill MJ, Gorry PR (2013). A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology, 2013, 10:43. * Contributed equally
Flynn JK, Paukovics G, Moore MS, Ellett A, Gray LR, Duncan R, Salimi H, Jubb B, Westby M, Purcell DF, Lewin SR, Churchill MJ, Gorry PR, and Roche M (2013). The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc imparts a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. Virology 2013, 442(1):51-8.
Roche M, Jakobsen MR, Ellett A, Salimi H, Jubb B, Westby M, Lee B, Lewin SR, Churchill MJ, Gorry PR (2011). HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology, 2011, 8(89).
Salimi H, Mokhtari-Azad T, Sarijloo M, Baesi K, Gooya M, Esteghamati A, Nategh R (2007). Seroepidemiology of rubella infection in 5-25 year old age group before and after measles/rubella mass vaccination on December 2003 in Iran. Journal of Infectious Disease and Tropical Medicine, 2007, 12(38): 39-42.
Copyright © 2011 The University of Iowa. All Rights Reserved.